Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

LONDON, February 6, 2013 /PRNewswire/ --

Pharma stocks performed fairly well lately. However, the main concern for all the major companies was related to the patent expiry of their blockbuster drugs. Amgen Inc. (NASDAQ: AMGN) is about to lose its patent exclusivity for its cancer drug Neupogen. However, the sector is also witnessing good merger and acquisition activities, where big players are acquiring smaller companies in order to make up the losses sustained through patent expirations. Smaller biotech companies are also betting big on developing drugs for various cancers, though the prospects do not look so bright. StockCall analysts have released their latest round of technical research on Amgen and Peregrine. This free research can be accessed by signing up now at

http://www.stockcall.com/registration

Amgen Provides Optimistic Projections

Amgen recently reported positive results for the fourth quarter. Its revenue grew 11.25 percent to $4.42 billion while its adjusted net income stood at $1.40 per share, beating consensus estimate of $1.39 per share in quarterly net income. Amgen expects its FY 2013 adjusted earnings to be in the range of $6.85 and $7.15 per share, while revenue is likely to be in the range of $17.8 billion and $18.2 billion, in comparison to $17.3 billion in revenue it earned for FY2012. Thus, while the company is likely to report better results, but the rate of growth is likely to be a little muted. However, Amgen surpassed consensus estimates for the projections. Register today and read our free technical report on Amgen at

http://www.StockCall.com/AMGN020613.pdf

The company also successfully conducted phase 3 of its cancer drug Neulasta. Amgen draws a big chunk
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... VIEW, Calif., July 31, 2014 IRIDEX Corporation (Nasdaq: ... second quarter and six months ended June 28, 2014.  ... of 2014, up 15% from $9.2 million in the 2013 ... first quarter of 2014. Revenues for the first six months ... in the first six months of last year. , ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5
... Medical Marijuana Inc. (OTC: MJNA) is proud to ... of PharmaSphere, LLC. PharmaSphere, a cutting edge biotechnology company ... value bio-compounds sourced from plants that can be used ... (genetically engineered plants) for the biotechnology revolution is the ...
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
Cached Medicine Technology:Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics 2Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics 3Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics 4FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:7/31/2014)... July 31, 2014 (HealthDay News) -- Transplant surgeons ... red flags for burnout, a new study suggests. ... the study reported having a low sense of ... to feeling emotionally exhausted, researchers found. "Burnout ... like transplantation," study co-author Dr. Marwan Abouljoud, director ...
(Date:7/31/2014)... Scientists have learned that recent fears of invasive lionfish ... efforts to control lionfish by fishing derbies and targeted ... invasion. And there,s a simple way to know for ... after it,s been cooked. , Pacific lionfish were first ... and have been gaining swiftly in number ever since. ...
(Date:7/31/2014)... July 31, 2014 Millions of people ... have had traumatic experiences as a child and some ... work. As a highly experienced NJ cosmetic dentist, ... anxiety during their dental procedure. To help these ... team at Champagne Smiles offer several sedation dentistry techniques. ...
(Date:7/31/2014)... Scotch Plains, New Jersey (PRWEB) July 31, 2014 ... certified dermatologist by the American Board of Dermatology, fellowship ... approved again by NJ Top Docs. , After extensive ... the National Institutes of Health, Dr. Li completed his ... dermatology training at the University of Pennsylvania in Philadelphia. ...
(Date:7/31/2014)... York (PRWEB) July 31, 2014 ... as Bernstein Liebhard LLP notes that Johnson & ... plans to voluntarily remove its power morcellators ( ... report from Bloomberg.com, the company said it decided ... associated with the devices remain uncertain.* , “In ...
Breaking Medicine News(10 mins):Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... Goodwin HealthDay Reporter , THURSDAY, May 10 ... children have little or no label information about drug ... "We still have a long way to go," ... of the U.S. Food and Drug Administration,s Office of ...
... , THURSDAY, May 10 (HealthDay News) -- A ... U.S. Food and Drug Administration showed promising results in ... took Qnexa, a combination of the drugs phentermine and ... many weight-related health problems, the study found. The findings ...
... a low haemoglobin (Hb) level do not respond well to ... survival are compromised. Now researchers from The Netherlands have found ... can be overcome by the use of a treatment known ... carbogen (a mixture of carbon dioxide and oxygen) and the ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... 2012) A review of 30 years of life-threatening asthma ... annual ICU admissions for the condition have dropped 74 percent. ... cases at University Hospital between 1980 and 2010, also showed ... not result in longer hospital stays. UT Medicine is ...
... severe complications from systemic sclerosis, also known as scleroderma, ... Rheumatism , a journal of the American College of ... were more likely to have antibodies that increased frequency ... decreased survival. According to the ACR there ...
Cached Medicine News:Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 2Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 3Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 2Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 3Health News:Economic theory actually works in health care 2Health News:ICU stays for worst asthma drop 74 percent, review finds 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: